How to buy AnaptysBio stock - 14 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy AnaptysBio stock

Own AnaptysBio stock in just a few minutes.

AnaptysBio, Inc is a biotechnology business based in the US. AnaptysBio shares (ANAB) are listed on the NASDAQ and all prices are listed in US Dollars. AnaptysBio employs 94 staff and has a trailing 12-month revenue of around USD$75 million.

How to buy shares in AnaptysBio

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for AnaptysBio. Find the stock by name or ticker symbol: ANAB. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until AnaptysBio reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of AnaptysBio, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of AnaptysBio. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

AnaptysBio share price

Use our graph to track the performance of ANAB stocks over time.

AnaptysBio shares at a glance

Information last updated 2021-04-08.
52-week rangeUSD$13.92 - USD$35.855
50-day moving average USD$23.7274
200-day moving average USD$24.1083
Wall St. target priceUSD$28.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-3.011

Buy AnaptysBio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy AnaptysBio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

AnaptysBio financials

Revenue TTM USD$75 million
Gross profit TTM USD$-5,025,000
Return on assets TTM -3.5%
Return on equity TTM -4.97%
Profit margin -26.58%
Book value $14.503
Market capitalisation USD$590.3 million

TTM: trailing 12 months

Shorting AnaptysBio shares

There are currently 3.9 million AnaptysBio shares held short by investors – that's known as AnaptysBio's "short interest". This figure is 3.3% up from 3.8 million last month.

There are a few different ways that this level of interest in shorting AnaptysBio shares can be evaluated.

AnaptysBio's "short interest ratio" (SIR)

AnaptysBio's "short interest ratio" (SIR) is the quantity of AnaptysBio shares currently shorted divided by the average quantity of AnaptysBio shares traded daily (recently around 885479.27927928). AnaptysBio's SIR currently stands at 4.44. In other words for every 100,000 AnaptysBio shares traded daily on the market, roughly 4440 shares are currently held short.

However AnaptysBio's short interest can also be evaluated against the total number of AnaptysBio shares, or, against the total number of tradable AnaptysBio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AnaptysBio's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 AnaptysBio shares in existence, roughly 140 shares are currently held short) or 0.2202% of the tradable shares (for every 100,000 tradable AnaptysBio shares, roughly 220 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against AnaptysBio.

Find out more about how you can short AnaptysBio stock.

AnaptysBio share dividends

We're not expecting AnaptysBio to pay a dividend over the next 12 months.

AnaptysBio share price volatility

Over the last 12 months, AnaptysBio's shares have ranged in value from as little as $13.92 up to $35.855. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AnaptysBio's is 0.0462. This would suggest that AnaptysBio's shares are less volatile than average (for this exchange).

AnaptysBio overview

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. It also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. AnaptysBio, Inc. has a collaboration and license agreement with TESARO, Inc. and Celgene Corporation; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site